食管癌新辅助免疫治疗研究进展

Research Progress of Neoadjuvant Immunotherapy for Esophageal Cancer

食管癌是一种侵袭性强、预后差的恶性肿瘤。尽管手术、化疗、放疗和靶向药物治疗结合,全球内的死亡率仍然很高。以帕博利珠单抗为代表的免疫检查点抑制剂被美国食品药品监督管理局(FDA)批准用于治疗食管癌,为食管癌的治疗提供了新的思路,经临床试验证实多种免疫检查点抑制剂在食管癌中显示出良好的治疗效果。由于局部晚期的食管癌患者治疗效果不尽如人意,新辅助免疫治疗可以使肿瘤降期、增加手术机会、延长患者生存期,多项临床试验正在探索新辅助免疫治疗联合化疗、放化疗及免疫治疗食管癌患者的应用模式,现有资料显示,新辅助免疫治疗对于食管癌治疗极具潜力,因此,就目前新辅助免疫治疗在食管癌中的临床研究进行综述。

Esophageal cancer is an aggressive malignant tumor with poor prognosis.Despite a combination of surgery,chemotherapy,radiotherapy and targeted drug therapy,the global mortality rate remains high.Immune checkpoint inhibitors represented by pembrolizumab have been approved by the food and drug administration(FDA)for the treatment of esophageal cancer,providing new ideas for the treatment of esophageal cancer.Clinical trials have confirmed that a variety of immunocheckpoint inhibitors show good therapeutic effects in esophageal cancer.Due to the effect of treatment of locally advanced esophageal cancer patients,new adjuvant immunotherapy can make tumor reduction period,increase the chance of operation,prolong patient survival,a number of clinical trials are exploring new adjuvant immunotherapy combined chemotherapy,chemoradiation and application patterns of immune therapy in patients with esophageal cancer,according to existing neoadjuvant immune therapy for esophageal cancer therapeutic potential.This article reviews the clinical research of neoadjuvant immunotherapy in esophageal cancer.